Induced Pluripotent Stem Cells Derived from a CLN5 Patient Manifest Phenotypic Characteristics of Neuronal Ceroid Lipofuscinoses

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2017 May 5

PMID 28468312

Citations 17

Authors

Kristiina Uusi-Rauva

Tea Blom

Carina von Schantz-Fant

Tomas Blom

Anu Jalanko

Aija Kyttala

Affiliations

Soon will be listed here.

Abstract

Neuronal ceroid lipofuscinoses (NCLs) are autosomal recessive progressive encephalopathies caused by mutations in at least 14 different genes. Despite extensive studies performed in different NCL animal models, the molecular mechanisms underlying neurodegeneration in NCLs remain poorly understood. To model NCL in human cells, we generated induced pluripotent stem cells (iPSCs) by reprogramming skin fibroblasts from a patient with CLN5 (ceroid lipofuscinosis, neuronal, 5) disease, the late infantile variant form of NCL. These CLN5 patient-derived iPSCs (CLN5Y392X iPSCs) harbouring the most common mutation, c.1175_1176delAT (p.Tyr392X), were further differentiated into neural lineage cells, the most affected cell type in NCLs. The CLN5Y392X iPSC-derived neural lineage cells showed accumulation of autofluorescent storage material and subunit C of the mitochondrial ATP synthase, both representing the hallmarks of many forms of NCLs, including CLN5 disease. In addition, we detected abnormalities in the intracellular organelles and aberrations in neuronal sphingolipid transportation, verifying the previous findings obtained from -deficient mouse macrophages. Therefore, patient-derived iPSCs provide a suitable model to study the mechanisms of NCL diseases.

Citing Articles

Polymer-based drug delivery systems under investigation for enzyme replacement and other therapies of lysosomal storage disorders.

Placci M, Giannotti M, Muro S Adv Drug Deliv Rev. 2023; 197:114683.

PMID: 36657645 PMC: 10629597. DOI: 10.1016/j.addr.2022.114683.

Secondary Mitochondrial Dysfunction as a Cause of Neurodegenerative Dysfunction in Lysosomal Storage Diseases and an Overview of Potential Therapies.

Stepien K, Cufflin N, Donald A, Jones S, Church H, Hargreaves I Int J Mol Sci. 2022; 23(18).

PMID: 36142486 PMC: 9503973. DOI: 10.3390/ijms231810573.

Glial Dysfunction and Its Contribution to the Pathogenesis of the Neuronal Ceroid Lipofuscinoses.

Takahashi K, Nelvagal H, Lange J, Cooper J Front Neurol. 2022; 13:886567.

PMID: 35444603 PMC: 9013902. DOI: 10.3389/fneur.2022.886567.

Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview.

Simonati A, Williams R Front Neurol. 2022; 13:811686.

PMID: 35359645 PMC: 8961688. DOI: 10.3389/fneur.2022.811686.

as a Model for Investigating Neurodegenerative Diseases.

Haver H, Scaglione K Front Cell Neurosci. 2021; 15:759532.

PMID: 34776869 PMC: 8578527. DOI: 10.3389/fncel.2021.759532.

References

Santavuori P . Neuronal ceroid-lipofuscinoses in childhood. Brain Dev. 1988; 10(2):80-3. DOI: 10.1016/s0387-7604(88)80075-5. View

El Haddad S, Khoury M, Daoud M, Kantar R, Harati H, Mousallem T . CLN5 and CLN8 protein association with ceramide synthase: biochemical and proteomic approaches. Electrophoresis. 2012; 33(24):3798-809. DOI: 10.1002/elps.201200472. View

von Schantz C, Saharinen J, Kopra O, Cooper J, Gentile M, Hovatta I . Brain gene expression profiles of Cln1 and Cln5 deficient mice unravels common molecular pathways underlying neuronal degeneration in NCL diseases. BMC Genomics. 2008; 9:146. PMC: 2323392. DOI: 10.1186/1471-2164-9-146. View

Autti T, Raininko R, Launes J, Nuutila A, Santavuori P . Jansky-Bielschowsky variant disease: CT, MRI, and SPECT findings. Pediatr Neurol. 1992; 8(2):121-6. DOI: 10.1016/0887-8994(92)90032-t. View

Holmberg V, Jalanko A, Isosomppi J, Fabritius A, Peltonen L, Kopra O . The mouse ortholog of the neuronal ceroid lipofuscinosis CLN5 gene encodes a soluble lysosomal glycoprotein expressed in the developing brain. Neurobiol Dis. 2004; 16(1):29-40. DOI: 10.1016/j.nbd.2003.12.019. View

Mancini C, Nassani S, Guo Y, Chen Y, Giorgio E, Brussino A . Adult-onset autosomal recessive ataxia associated with neuronal ceroid lipofuscinosis type 5 gene (CLN5) mutations. J Neurol. 2014; 262(1):173-8. DOI: 10.1007/s00415-014-7553-y. View

Santavuori P, Rapola J, Sainio K, Raitta C . A variant of Jansky-Bielschowsky disease. Neuropediatrics. 1982; 13(3):135-41. DOI: 10.1055/s-2008-1059612. View

Mole S, Cotman S . Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochim Biophys Acta. 2015; 1852(10 Pt B):2237-41. PMC: 4567481. DOI: 10.1016/j.bbadis.2015.05.011. View

Schmiedt M, Bessa C, Heine C, Ribeiro M, Jalanko A, Kyttala A . The neuronal ceroid lipofuscinosis protein CLN5: new insights into cellular maturation, transport, and consequences of mutations. Hum Mutat. 2010; 31(3):356-65. DOI: 10.1002/humu.21195. View

10.

Tyynela J, Suopanki J, Santavuori P, Baumann M, Haltia M . Variant late infantile neuronal ceroid-lipofuscinosis: pathology and biochemistry. J Neuropathol Exp Neurol. 1997; 56(4):369-75. DOI: 10.1097/00005072-199704000-00005. View

11.

Best H, Neverman N, Wicky H, Mitchell N, Leitch B, Hughes S . Characterisation of early changes in ovine CLN5 and CLN6 Batten disease neural cultures for the rapid screening of therapeutics. Neurobiol Dis. 2017; 100:62-74. DOI: 10.1016/j.nbd.2017.01.001. View

12.

Lyly A, Marjavaara S, Kyttala A, Uusi-Rauva K, Luiro K, Kopra O . Deficiency of the INCL protein Ppt1 results in changes in ectopic F1-ATP synthase and altered cholesterol metabolism. Hum Mol Genet. 2008; 17(10):1406-17. DOI: 10.1093/hmg/ddn028. View

13.

Savukoski M, Klockars T, Holmberg V, Santavuori P, Lander E, Peltonen L . CLN5, a novel gene encoding a putative transmembrane protein mutated in Finnish variant late infantile neuronal ceroid lipofuscinosis. Nat Genet. 1998; 19(3):286-8. DOI: 10.1038/975. View

14.

Zhang Z, Lee Y, Kim S, Choi M, Tsai P, Xu Y . Palmitoyl-protein thioesterase-1 deficiency mediates the activation of the unfolded protein response and neuronal apoptosis in INCL. Hum Mol Genet. 2005; 15(2):337-46. DOI: 10.1093/hmg/ddi451. View

15.

Nat R, Nilbratt M, Narkilahti S, Winblad B, Hovatta O, Nordberg A . Neurogenic neuroepithelial and radial glial cells generated from six human embryonic stem cell lines in serum-free suspension and adherent cultures. Glia. 2006; 55(4):385-99. DOI: 10.1002/glia.20463. View

16.

Faller K, Gutierrez-Quintana R, Mohammed A, Rahim A, Tuxworth R, Wager K . The neuronal ceroid lipofuscinoses: Opportunities from model systems. Biochim Biophys Acta. 2015; 1852(10 Pt B):2267-78. DOI: 10.1016/j.bbadis.2015.04.022. View

17.

Kollmann K, Uusi-Rauva K, Scifo E, Tyynela J, Jalanko A, Braulke T . Cell biology and function of neuronal ceroid lipofuscinosis-related proteins. Biochim Biophys Acta. 2013; 1832(11):1866-81. DOI: 10.1016/j.bbadis.2013.01.019. View

18.

Staropoli J, Xin W, Barone R, Cotman S, Sims K . An atypical case of neuronal ceroid lipofuscinosis with co-inheritance of a variably penetrant POLG1 mutation. BMC Med Genet. 2012; 13:50. PMC: 3443422. DOI: 10.1186/1471-2350-13-50. View

19.

Schmiedt M, Blom T, Blom T, Kopra O, Wong A, von Schantz-Fant C . Cln5-deficiency in mice leads to microglial activation, defective myelination and changes in lipid metabolism. Neurobiol Dis. 2011; 46(1):19-29. DOI: 10.1016/j.nbd.2011.12.009. View

20.

Bond M, Kleine Holthaus S, Tammen I, Tear G, Russell C . Use of model organisms for the study of neuronal ceroid lipofuscinosis. Biochim Biophys Acta. 2013; 1832(11):1842-65. DOI: 10.1016/j.bbadis.2013.01.009. View